Cerebrospinal Fluid Gravity Correlation Analysis

NCT ID: NCT05644535

Last Updated: 2022-12-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-12-01

Study Completion Date

2023-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study was to measure cerebrospinal fluid density in aged patients and to see if there was a correlation between these factors and cerebrospinal fluid density by using the electronic medical record system to understand the patient's gender, blood glucose, blood biochemical electrolytes and blood levels.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hip joint injury is one of the common injuries in the elderly, and hip arthroplasty is a treatment method that allows patients to get out of bed and return to social life as soon as possible. Currently, the common position for hip arthroplasty is the lateral position; and combined spinal and epidural anesthesia or subarachnoid anesthesia is also the common anesthesia method for hip arthroplasty. In the lateral position, the patient's affected limb is often on top and the healthy limb is on the bottom; the healthy side position is also the usual position for hip arthroplasty. In this position, it may be optimal to use a lighter specific gravity local anesthetic drug because it tends to anesthetize only the upper affected limb and does not require a return to the supine position after anesthesia due to changes in the plane of block, minimizing pain and hemodynamic fluctuations during anesthesia and position changes.

Currently, light specific gravity is more of a concept. Because in the available data, only the range of cerebrospinal fluid density of ordinary healthy adults is available, there is little literature and data to describe and analyze what the cerebrospinal fluid density of elderly patients actually is. Therefore, when we administer subarachnoid anesthesia to elderly patients, we cannot determine whether the dispensed local anesthetic drug is a light specific gravity.

In this study, we intend to collect cerebrospinal fluid from elderly patients who underwent hip arthroplasty under combined lumbar and rigid anesthesia or subarachnoid anesthesia, and measure the cerebrospinal fluid density in elderly patients, and observe whether there is a correlation between the above factors and cerebrospinal fluid density through the electronic medical record system to understand the patient's gender, blood glucose, blood biochemical electrolytes and routine blood levels; thus, we can better guide the use of lighter specific gravity drugs in clinical practice.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Specific Gravity Cerebrospinal Fluid

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Cerebrospinal fluid Correlation Analysis Lighter Specific Gravity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

ECOLOGIC_OR_COMMUNITY

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

Patients were aged 60-69 years

Cerebrospinal fluid densitometry

Intervention Type DIAGNOSTIC_TEST

After obtaining the patient's cerebrospinal fluid specimen, the actual mass of the cerebrospinal fluid was measured by pipetting 1000 μL of cerebrospinal fluid specimen on an analytical balance using a pipette gun, and all specimens were measured three times and the average of the three times was taken as the final mass of 1000 μL of that specimen. After the mass measurement, the residual cerebrospinal fluid was disposed of as medical waste. The density of each specimen was obtained according to the density to mass conversion formula ρ=m/v.

blood routine examination

Intervention Type DIAGNOSTIC_TEST

After obtaining the patient's blood specimens, they were sent to the laboratory for blood routine examination.

Blood electrolyte examination

Intervention Type DIAGNOSTIC_TEST

After obtaining the patient's blood specimens, they were sent to the laboratory for blood electrolyte examination.

Group B

Patients were aged 70-79 years

Cerebrospinal fluid densitometry

Intervention Type DIAGNOSTIC_TEST

After obtaining the patient's cerebrospinal fluid specimen, the actual mass of the cerebrospinal fluid was measured by pipetting 1000 μL of cerebrospinal fluid specimen on an analytical balance using a pipette gun, and all specimens were measured three times and the average of the three times was taken as the final mass of 1000 μL of that specimen. After the mass measurement, the residual cerebrospinal fluid was disposed of as medical waste. The density of each specimen was obtained according to the density to mass conversion formula ρ=m/v.

blood routine examination

Intervention Type DIAGNOSTIC_TEST

After obtaining the patient's blood specimens, they were sent to the laboratory for blood routine examination.

Blood electrolyte examination

Intervention Type DIAGNOSTIC_TEST

After obtaining the patient's blood specimens, they were sent to the laboratory for blood electrolyte examination.

Group C

Patients were aged 80-89 years

Cerebrospinal fluid densitometry

Intervention Type DIAGNOSTIC_TEST

After obtaining the patient's cerebrospinal fluid specimen, the actual mass of the cerebrospinal fluid was measured by pipetting 1000 μL of cerebrospinal fluid specimen on an analytical balance using a pipette gun, and all specimens were measured three times and the average of the three times was taken as the final mass of 1000 μL of that specimen. After the mass measurement, the residual cerebrospinal fluid was disposed of as medical waste. The density of each specimen was obtained according to the density to mass conversion formula ρ=m/v.

blood routine examination

Intervention Type DIAGNOSTIC_TEST

After obtaining the patient's blood specimens, they were sent to the laboratory for blood routine examination.

Blood electrolyte examination

Intervention Type DIAGNOSTIC_TEST

After obtaining the patient's blood specimens, they were sent to the laboratory for blood electrolyte examination.

Group D

Patient age \> 90 years

Cerebrospinal fluid densitometry

Intervention Type DIAGNOSTIC_TEST

After obtaining the patient's cerebrospinal fluid specimen, the actual mass of the cerebrospinal fluid was measured by pipetting 1000 μL of cerebrospinal fluid specimen on an analytical balance using a pipette gun, and all specimens were measured three times and the average of the three times was taken as the final mass of 1000 μL of that specimen. After the mass measurement, the residual cerebrospinal fluid was disposed of as medical waste. The density of each specimen was obtained according to the density to mass conversion formula ρ=m/v.

blood routine examination

Intervention Type DIAGNOSTIC_TEST

After obtaining the patient's blood specimens, they were sent to the laboratory for blood routine examination.

Blood electrolyte examination

Intervention Type DIAGNOSTIC_TEST

After obtaining the patient's blood specimens, they were sent to the laboratory for blood electrolyte examination.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cerebrospinal fluid densitometry

After obtaining the patient's cerebrospinal fluid specimen, the actual mass of the cerebrospinal fluid was measured by pipetting 1000 μL of cerebrospinal fluid specimen on an analytical balance using a pipette gun, and all specimens were measured three times and the average of the three times was taken as the final mass of 1000 μL of that specimen. After the mass measurement, the residual cerebrospinal fluid was disposed of as medical waste. The density of each specimen was obtained according to the density to mass conversion formula ρ=m/v.

Intervention Type DIAGNOSTIC_TEST

blood routine examination

After obtaining the patient's blood specimens, they were sent to the laboratory for blood routine examination.

Intervention Type DIAGNOSTIC_TEST

Blood electrolyte examination

After obtaining the patient's blood specimens, they were sent to the laboratory for blood electrolyte examination.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Receiving combined spinal and epidural anesthesia or subarachnoid anesthesia ASA Ⅰ or Ⅱ patients No significant neurological pathology No recent history of cerebral infarction No recent history of cerebral hemorrhage No central nervous system inflammation No spinal inflammatory disease No history of spinal surgery Patients who have given pre-operative informed written consent

Exclusion Criteria

\-
Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

First People's Hospital of Chenzhou

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

zhiming zhang

MD, Ph.D

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Zhiming Zhang

Chenzhou, Hunan, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Zhiming Zhang

Role: CONTACT

Phone: +8613875555649

Email: [email protected]

Yuan Qin

Role: CONTACT

Phone: 13657381087

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Zhiming Zhang, M.D.

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

202201

Identifier Type: -

Identifier Source: org_study_id